The role of chemokines in migration of metastatic-like lymphangioleiomyomatosis cells

Critical Reviews in Immunology

Volumn 30, Issue 4, 2010, Pages 387-394

  Pacheco Rodriguez, Gustavo ^a   Moss, Joel ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

cell motility; chemokine receptors; chemokines; cystic lung disease; lymphangioleiomyomatosis; mammalian target of rapamycin; metastasis; smooth muscle cells; tuberous sclerosis complex

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; GLYCOPROTEIN GP 100; HAMARTIN; MAMMALIAN TARGET OF RAPAMYCIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TUBERIN; TUBEROUS SCLEROSIS 1 PROTEIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; CELL MIGRATION; CELL MOTILITY; HUMAN; INNATE IMMUNITY; LUNG FUNCTION; LUNG NODULE; LYMPHANGIOLEIOMYOMATOSIS; MELANOMA; MELANOMA CELL; METASTASIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SMOOTH MUSCLE FIBER; TUMOR CELL; ANIMAL; CELL MOTION; IMMUNOLOGY; LUNG TUMOR; PATHOLOGY;

ANIMALS; CELL MOVEMENT; CHEMOKINES; HUMANS; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; NEOPLASM METASTASIS; RECEPTORS, CHEMOKINE;

EID: 77954911176     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevimmunol.v30.i4.40     Document Type: Review

References (54)

1. RyuJH, Moss J, Beck GJ, Lee JC, Brown KK, Chapman JT, Finlay GA, Olson EJ, Ruoss SJ, Maurer JR, Raffin TA, Peavy HH, McCarthy K, Taveira-Dasilva A, McCormack FX, Avila NA, Decastro RM, Jacobs SS, Stylianou M, Fanburg BL; NHLBI LAM Registry Group. The nhlbi lymphangioleiomyomatosis registry: Characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006;173:105-111
2. Taveira-DaSilva AM, Steagall WK, Moss J. Lymphangioleiomyomatosis. Cancer Control. 2006;13:276-285
3. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355:1345-1356.
4. Folpe AL, Kwiatkowski DJ. Perivascular epithelioid cell neoplasms: pathology and pathogenesis. Hum Pathol. 2010;41:1-15.
5. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene tsc2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2000;97:6085-6090
6. Huang J, Manning BD. The tsc1-tsc2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008;412:179-190
7. Bittmann I, Dose TB, Muller C, Dienemann H, Vogelmeier C, Lohrs U. Lymphangioleiomyomatosis: recurrence after single lung transplantation. Hum Pathol. 1997;28:1420-1423
8. Bittmann I, Rolf B, Amann G, Lohrs U. Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Hum Pathol. 2003;34:95-98
9. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, McCoy JP Jr, Wang JA, Kumaki F, Darling T, Moss J. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2004;101:17462-17467
10. Zlotnik A. Chemokines and cancer. Int J Cancer. 2006;119:2026-2029
11. Fidler IJ, Poste G. The 'seed and soil' hypothesis revisited. Lancet Oncol. 2008;9:808.
12. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56
13. Martignoni G, Pea M, Reghellin D, Zamboni G, Bonetti F. Pecomas: The past, the present and the future. Virchows Arch. 2008;452:119-132
14. McCormack FX. Lymphangioleiomyomatosis. MedGenMed. 2006 Jan 18;8:15
15. Wullschleger S, Loewith R, Hall MN. Tor signaling in growth and metabolism. Cell. 2006;124:471-484
16. Huang J, Manning BD. A complex interplay between akt, tsc2 and the two mtor complexes. Biochem Soc Trans. 2009;37:217-222
17. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol. 2003;5:578-581
18. Inoki K, Li Y, Xu T, Guan KL. Rheb gtpase is a direct target of tsc2 gap activity and regulates mtor signaling. Genes Dev. 2003;17:1829-1834
19. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, tuberin and hamartin, control mtor signaling by acting as a gtpase-activating protein complex toward rheb. Curr Biol. 2003;13:1259-1268
20. Henske EP. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer. 2003;38:376-381
21. Kumasaka T, Seyama K, Mitani K, Souma S, Kashiwagi S, Hebisawa A, Sato T, Kubo H, Gomi K, Shibuya K, Fukuchi Y, Suda K. Lymphangiogenesis-mediated shedding of lam cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol. 2005;29:1356-1366
22. Bacac M, Stamenkovic I. Metastatic cancer cell. Annu Rev Pathol. 2008;3:221-247
23. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature. 1980;283:139-146
24. Hart IR, Fidler IJ. Role of organ selectivity in the determination of metastatic patterns of b16 melanoma. Cancer Res. 1980;40:2281-2287
25. Rollins BJ. Chemokines. Blood. 1997;90:909-928
26. O'Hayre M, Salanga CL, Handel TM, Allen SJ. Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J. 2008;409:635-649
27. Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 2004;25:75-84.
28. Goncharova EA, Goncharov DA, Lim PN, Noonan D, Krymskaya VP. Modulation of cell migration and invasiveness by tumor suppressor tsc2 in lymp- hangioleiomyomatosis. Am J Respir Cell Mol Biol. 2006;34:473-480
29. Goncharova E, Goncharov D, Noonan D, Krymskaya VP. Tsc2 modulates actin cytoskeleton and focal adhesion through tsc1-binding domain and the rac1 gtpase. J Cell Biol. 2004;167:1171-1182
30. Pacheco-Rodriguez G, Kumaki F, Steagall WK, Zhang Y, Ikeda Y, Lin JP, Billings EM, Moss J. Chemokine- enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor tsc2 gene. J Immunol. 2009;182:1270-1277
31. Li S, Takeuchi F, Wang JA, Fuller C, Pacheco-Rodriguez G, Moss J, Darling TN. Mcp-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development. J Exp Med. 2005;202:617-624
32. Govindarajan B, Brat DJ, Csete M, Martin WD, Murad E, Litani K, Cohen C, Cerimele F, NunnelleyM, Lefkove B, Yamamoto T, Lee C, Arbiser JL. Transgenic expression of dominant negative tuberin through a strong constitutive promoter results in a tissue-specific tuberous sclerosis phenotype in the skin and brain. J Biol Chem. 2005;280:5870-5874
33. Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, Kolbe T, Stulnig TM, H6rl WH, Hengstschlager M, Muller M, Saemann MD. The tsc-mtor signaling pathway regulates the innate inflammatory response. Immunity. 2008;29:565-577
34. Wu X, Lee VC, Chevalier E, Hwang ST. Chemokine receptors as targets for cancer therapy. Curr Pharm Des. 2009;15:742-757
35. Rodriguez-Frade JM, Mellado M, Martinez AC. Chemokine receptor dimerization: two are better than one. Trends Immunol. 2001;22:612-617
36. Wang J, Norcross M. Dimerization of chemokine receptors in living cells: key to receptor function and novel targets for therapy. Drug Discov Today. 2008;13:625-632
37. Balkwill F. The significance of cancer cell expression of the chemokine receptor cxcr4. Semin Cancer Biol. 2004;14:171-179
38. Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett. 2007;256:137-165
39. Robledo MM, Bartolome RA, Longo N, Rodriguez- Frade JM, Mellado M, Longo I, van Muijen GN, Sanchez-Mateos P, Teixido J. Expression of functional chemokine receptors cxcr3 and cxcr4 on human melanoma cells. J Biol Chem. 2001;276:45098-45105
40. Clements D, Markwick LM, Johnson SR. The cxcr4/ cxcl12 axis in lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2009;179:A4350.
41. Darash-Yahana M, Gillespie JW, Hewitt SM, Chen YY, Maeda S, Stein I, Singh SP, Bedolla RB, Peled A, Troyer DA, Pikarsky E, Karin M, Farber JM. The chemokine cxcl16 and its receptor, cxcr6, as markers and promoters of inflammation-associated cancers. PLoS One. 2009;4:e6695.
42. Wang J, Lu Y, Koch AE, Zhang J, Taichman RS. Cxcr6 induces prostate cancer progression by the akt/ mammalian target of rapamycin signaling pathway. Cancer Res. 2008;68:10367-10376
43. Murakami T, Cardones AR, Finkelstein SE, Restifo NP, Klaunberg BA, Nestle FO, Castillo SS, Dennis PA, Hwang ST. Immune evasion by murine melanoma mediated through cc chemokine receptor-10. J Exp Med. 2003;198:1337-1347
44. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC. Upregulation of cxcr4 is essential for her2-mediated tumor metastasis. Cancer Cell. 2004;6:459-469
45. Taveira-DaSilva AM, Hedin C, Stylianou MP, Travis WD, Matsui K, Ferrans VJ, Moss J. Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2001;164:1072-1076
46. Ryu JH, Myers JL, Swensen SJ. Bronchiolar disorders. Am J Respir Crit Care Med. 2003;168:1277-1292
47. Kayisli UA, Mahutte NG, Arici A. Uterine chemok- ines in reproductive physiology and pathology. Am J Reprod Immunol. 2002;47:213-221
48. Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, Astrinidis A, Wang C, Hernandez-Cuebas L, Seeholzer LF, Nicolas E, Hensley H, Jordan VC, Walker CL, Henske EP. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A. 2009;106:2635-2640
49. Yang G, Rosen DG, Zhang Z, Bast RC Jr, Mills GB, Colacino JA, Mercado-Uribe I, Liu J. The chemokine growth-regulated oncogene 1 (gro-1) links ras signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A. 2006;103:16472-16477
50. Ancrile BB, O'Hayer KM, Counter CM. Oncogenic ras-induced expression of cytokines: A new target of anti-cancer therapeutics. Mol Interv. 2008;8:22-27
51. Pacheco-Rodriguez G, Steagall WK, Crooks DM, Stevens LA, Hashimoto H, Li S, Wang JA, Darling TN, Moss J. Tsc2 loss in lymphangioleiomyoma- tosis cells correlated with expression of cd44v6, a molecular determinant of metastasis. Cancer Res. 2007;67:10573-10581
52. Ponta H, Sherman L, Herrlich PA. Cd44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4:33-45.
53. Matsui K, Takeda K, Yu ZX, Travis WD, Moss J, Ferrans VJ. Role for activation of matrix metal- loproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med. 2000;124:267-275
54. Ferrans VJ, Yu ZX, Nelson WK, Valencia JC, Tatsuguchi A, Avila NA, Riemenschn W, Matsui K, Travis WD, Moss J. Lymphangioleiomyomatosis (lam): A review of clinical and morphological features. J Nippon Med Sch. 2000;67:311-329